Announcements Trials
Browse Landscape

Status

Recruiting 3Unknown 1Completed 1

Sponsor Class

OTHER 5

Study Type

Interventional 120Observational 5Expanded_access 1

Sponsor

Cancer Type

Breast 5CNS 2

Conditions

Breast Neoplasms 4Brain Neoplasms 2Triple Negative Breast Neoplasms 1Neoplasm Metastasis 1Drug-Related Side Effects and Adverse Reactions 1

Interventions

Surveys and Questionnaires 543Blood Specimen Collection 446Surgical Procedures, Operative 164Observation 152Drug Therapy 142Radiotherapy 141Interviews as Topic 139Gene Expression Profiling 129Biopsy 117Magnetic Resonance Spectroscopy 116Immunohistochemistry 112Data Collection 95Polymerase Chain Reaction 87Specimen Handling 81Amplified Fragment Length Polymorphism Analysis 81Bevacizumab 78Microarray Analysis 76Flow Cytometry 69Neoadjuvant Therapy 68Watchful Waiting 66Magnetic Resonance Imaging 65Immune Checkpoint Inhibitors 61Nivolumab 60Immunotherapy 57Therapeutics 55Reverse Transcriptase Polymerase Chain Reaction 52pembrolizumab 50Ultrasonography 47Positron Emission Tomography Computed Tomography 47Hematologic Tests 46

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Observational × sacituzumab govitecan × Clear all
NCT07582887 2026-05-13

Impact of Genetic Variants on the Toxicity of Antibody-Drug Conjugates in Locally Advanced or Metastatic Breast Cancer: The Role of the UGT1A1 Gene as a Predictive Biomarker of Therapeutic Response

Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental

Recruiting
70 enrolled
Breast

Breast Neoplasms, Drug-Related Side Effects and Adverse Reactions

NCT07251868 2025-11-26

Evaluation of Trop-2 ADC in Breast Cancer Patients With Brain Metastases: A Real-World Study

Peking University Cancer Hospital & Institute

Recruiting
100 enrolled
BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT06504719 2025-09-15

Safety and Efficacy Real-world Data of Trastuzumab Deruxtecan and Sacituzumab Govitecan

Hellenic Cooperative Oncology Group

Completed
312 enrolled
BreastCNS

Brain Neoplasms, Breast Neoplasms, Neoplasm Metastasis

NCT06991790 2025-05-28

Sacituzumab Govitecan + Toripalimab as First - Line Therapy for Advanced Triple - Negative Breast Cancer and Biomarker Exploration

Peking University Cancer Hospital & Institute

Recruiting
51 enrolled
Breast

Triple Negative Breast Neoplasms

NCT06356519 2024-04-10

Real-world Effectiveness and Safety Study of Sacituzumab Govitecan in Chinese Metastatic Breast Cancer

Fudan University

Unknown
150 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡